Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder

NCT06878976 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Binge-Eating Disorder

Interventions

DRUG: Solriamfetol 75mg, 150 mg, or 300 mg

Sponsor

Axsome Therapeutics, Inc.